Sahajanand Medical Technologies Ltd. వార్షిక వృద్ధి వివరాలు ఆధారంగా కంపెనీ చరిత్ర

Our Company was initially formed as a partnership firm named ‘M/s Sahajanand Vascular Technoventions’ pursuant to a partnership deed dated October 25, 1999 between two partners namely, Sharada Dhirajlal Kotadia and Rajesh Laljibhai Vaishnav. Subsequently, pursuant to a partnership deed dated September 30, 2001, between Sharada Dhirajlal Kotadia, Rajesh Laljibhai Vaishnav, Dhirajlal Vallabhbhai Kotadia, Dhirajkumar Savjibhai Vasoya, Vinod Savjibhai Vasoya, Jitendra V. Kotadia and Nayna Dhirajkumar Vasoya (collectively, the “Partners”), the partnership firm was re-constituted, and the name of the partnership firm was changed to ‘M/s Sahajanand Medical Technologies’.

The partnership firm was subsequently converted into a joint stock company and was registered as a private limited company named ‘Sahajanand Medical Technologies Private Limited’ pursuant to a certificate of incorporation dated October 18, 2001, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli, in accordance with provisions of the Companies Act, 1956. Subsequently, our Company was converted into a public limited company as approved by a resolution of our Board dated March 10, 2021 and the special resolution dated April 27, 2021 passed by the Shareholders of our Company, following which the name of our Company was changed to ‘Sahajanand Medical Technologies Limited’ and a fresh certificate of incorporation was issued by the RoC on May 7, 2021.

2016

- Samara Capital Markets Holding Limited invested around ? 400 million by subscribing to 9,406,419 Equity Shares of our Company. Additionally, Samara Capital Markets Holding Limited also purchased 9,406,419 Equity Shares of our Company from existing shareholders for a consideration around ? 400 million

2017

- Samara Capital Markets Holding Limited invested ? 700 million by subscribing to 13,717,421 Equity Shares of our Company

- Enrolment of 1,435 patients completed for TALENT trial on the safety and efficacy of a sirolimus eluting coronary stent

2018

- NHPEA Sparkle Holding B.V. invested ? 1,600 million by subscribing to 16,396,803 Equity Shares of our Company

2019

- TALENT trial study for Supraflex presented by Professor Patrick Serruys and published in The Lancet

- Received EC Certificate for full quality assurance system granted to Supraflex Cruz

- Acquired Imex Salud S.L. to establish direct operations in Spain, for a sum of € 2.55 million

- Acquired 75% of the quotas of SMT Brazil (erstwhile Zarek Distribuidora De Produtos Hospitalares Eireli) to establish hybrid operations in Brazil, for a sum of R$ 18.82 million

2020

- Acquired VCL (as an erstwhile subsidiary of our Company) for a consideration of ? 687.29 million

- Acquired Vascular Innovations, a wholly owned subsidiary of SMT Ireland, for a sum of ? 443.00 million

2022

- Publication of the safety and performance study of “Hydra TAVI” in JACC: Cardiovascular Interventions, demonstrating its efficacy in the treatment of symptomatic severe aortic stenosis

2024

- Launch of Hydra TAVI in Russia, Malaysia and Hungary

- Completion of patient enrolment for TUXEDO-2, a clinical trial to evaluate the efficacy of drug eluting stent “Supraflex Cruz” in diabetic patients with multi vessel coronary artery disease

- TGA Australia’s approval for drug eluting stent “Supraflex Cruz”

- Publication of S-FLEX UK-II Registry study on “Supraflex Cruz” demonstrating its clinical safety and performance in BMJ Open

- Publication of the Compare 60/80 HBR trial study in Circulation: Cardiovascular Interventions demonstrating the efficacy of “Supraflex Cruz” in high bleeding risk patients

2025

- SMT Ireland, our wholly owned Subsidiary, purchased shares of the common stock of SNP Medical Corporation

- Publication of 3 year follow up outcomes of the FIRE Trial of “Supraflex Cruz” in Jama Cardiology, demonstrating sustained clinical benefits of Supraflex Cruz in older patients (>75 years) with myocardial infarction and multivessel disease

- Publication of 30 day and 6 months follow up outcomes of the GENESIS -II study of Hydra Transcatheter heart valve device in Asia Intervention and Euro PCR 2025, respectively, demonstrating its safety and performance in treating severe aortic stenosis in high risk patients

- Presentation of the results of TUXEDO-2, multivessel TALENT trial and Cruz Senior Study, along with results of SFlex Netherlands Registry demonstrating the non inferiority, proven safety, efficacy, and consistent performance of the Supraflex Cruz across a broad spectrum of complex patient populations, at Transcatheter Cardiovascular Therapeutics 2025